DDInter898 DDInter1676
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ibritumomab tiuxetan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palifermin
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Antithrombin Alfa
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Abciximab
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Ketorolac
Ibritumomab tiuxetan may cause a minor interaction that can limit clinical effects when taken with Capsicum
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Palifermin
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Antithrombin Alfa
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Abciximab
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Ketorolac